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■ Abstract
Background: We present the results obtained from the largest series of in vitro diagnostic tests ever reported in patients with clinically validated 
hypersensitivity to acetylsalicylic acid (ASA)/nonsteroidal anti-infl ammatory drugs (NSAID) compared with various categories of controls tolerating 
ASA/NSAIDs. This multicenter study, which was performed within the framework of the European Network for Drug Allergy (ENDA) group, showed 
that the basophil activation test (BAT), particularly when used with the 3 NSAIDs aspirin (ASA), diclofenac (DIC), and naproxen (NAP), allows 
us to confi rm the diagnosis of NSAID hypersensitivity syndrome. The results of the cellular allergen stimulation test (CAST) frequently correlate 
with those of the BAT, although not always. An unexpected fi nding was that basophil activation by NSAIDs is not an all-or-nothing phenomenon 
restricted to clinically hypersensitive patients, but that it also occurs in a dose-related manner in some NSAID-tolerant control individuals. Therefore, 
NSAID hypersensitivity appears as a shift in the normal pharmacological response to NSAIDs.  These fi ndings allow us to formulate a new rational 
hypothesis about the mechanism of NSAID hypersensitivity syndrome, a mechanism that most authors continue to describe as “unknown.”
Methods: We enrolled 152 patients with a history of hypersensitivity to NSAIDs and 136 control participants in 11 different centers between 
spring 2003 and spring 2006. Flowcytometric BAT was performed.
Results: The most noteworthy results of our study were that 57% of 140 patients presented very clear-cut positive BAT results to multiple 
NSAIDs, and 16% were entirely negative. In about 27% of cases, positive results were obtained with 1 or 2 concentrations of a single 
NSAID. There is clearly a correlation between the results of BAT and CAST.
Conclusions: BAT seems particularly indicated in patients with a clinical history of NSAID intolerance, and in whom a provocation test is not 
advisable for ethical, clinical, or other reasons. Clear-cut positive results can be considered as confi rming a history of NSAID hypersensitivity, 
although negative results may not exclude it.
Key words: NSAID hypersensitivity syndrome. Clinical findings. In vitro diagnosis. Basophil activation test. Flowcytometry. 
Sulphidoleukotrienes.
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■ Resumen
Introducción: En este estudio presentamos los resultados obtenidos en la mayor serie sobre diagnóstico in vitro en pacientes con 
hipersensibilidad a aspirina/AINEs comparados con diferentes categorías de controles tolerantes. Este estudio multicéntrico, realizado en 
el marco del grupo ENDA (European Network Drug Allergy) confi rma que el TAB (Test de activación de basófi los), cuando se utiliza frente 
a aspirina, diclofenaco y naproxeno, permite confi rmar el diagnóstico de este síndrome. El CAST se correlaciona en algunos casos con 
el TAB. Un hallazgo inesperado es que el TAB frente a AINES no es un fenómeno restringido a los pacientes hipersensibles clínicamente 
sino que también ocurre en algunos individuos tolerantes de forma dosis-dependiente. Así, la hipersensibilidad a AINES aparece como 
una modifi cación de la respuesta farmacológica normal en respuesta a AINES. Estos hallazgos nos permiten formular una nueva hipótesis 
racional sobre el mecanismo de hipersensibilidad a AINES sobre el que la mayoría de los autores consideran que es desconocido.
Métodos: En este estudio se incluyeron 152 pacientes con historia de hipersensibilidad a AINES y 136 sujetos control recogidos en 11 
diferentes centros entre la primavera de 2003 y la de 2006. Se realizó el TAB.
Resultados: Los resultados más destacables de este estudio son los siguientes: el 57% de 140 pacientes presentó claros resultados 
positivos a múltiples AINES y en el 16% de los casos los resultados fueron completamente negativos. En aproximadamente un 27% de 
los casos, se obtuvieron resultados positivos con 1 o 2 concentraciones de un solo AINE. Existe una clara correlación entre los resultados 
del TAB y del CAST
Conclusiones: Esta técnica parece estar indicada especialmente en pacientes con historia clínica de intolerancia a AINES en los que el 
test de provocación no es aconsejable por razones éticas, clínicas u otras. Los resultados positivos en esta técnica confi rman la historia de 
hipersensibilidad a AINES, pero los resultados negativos no la excluyen.
Palabras clave: Síndrome de hipersensibilidad a AINES. Hallazgos clínicos. Diagnóstico in vitro. Test de activación de basófi los. Citometría 
de fl ujo. 
Introduction
Hypersensitivity to acetylsalicylic acid (ASA) and other 
nonsteroidal infl ammatory drugs (NSAIDs) is a well-known 
condition that was fi rst described as a syndrome by Widal [1] 
in 1922, and popularized by Samter and Beers [2] in the late 
1960s. This syndrome presents with respiratory manifestations 
(recurrent rhinitis associated with nasal polyposis and followed 
by asthma attacks—the classic ASA triad) or with cutaneous 
manifestations such as urticaria and angioedema. Both types 
can coexist, but this is more uncommon. The prevalence of 
hypersensitivity to ASA and NSAIDs has been shown in 
several studies to be about 10% to 20% in adult asthmatics 
and 0.6% to 2.5% in the general population [3,4]. A recent 
meta-analysis of available data indicates a higher prevalence 
of hypersensitivity in asthmatics after evaluation using oral 
challenge (adults 14% to 29%, children 0% to 14%) than by 
history alone (adults 2% to 4%, children 1% to 3%) [5]. It has 
been reported that untoward reactions to NSAIDs constitute 
20% to 25% of all hypersensitivity reactions to drugs [6]. The 
main features, clinical manifestations, pathogenesis, diagnosis, 
treatment, and prevention of NSAID hypersensitivity 
syndrome are well documented [3,7-10]. With the possible 
exception of rare cases of anaphylactic shock, which may 
be associated with specifi c immunoglobulin (Ig) E [11,12], 
hypersensitivity to ASA and NSAIDs is widely believed not 
to be associated with a mechanism other than Ig. Many years 
ago, it was proposed [13-15] that the reaction was generated 
by inhibition of cyclooxygenase (COX) by ASA-like drugs 
in the airways or in the skin of hypersensitive patients. This 
theory has recently been restricted to inhibition of the COX-1 
enzyme, which diminishes the production of prostaglandin 
E
2
 (PGE
2
) that normally acts as a “brake” on the production 
of the sulfi doleukotrienes (sLT) LTC
4
, LTD
4
, and LTE
4
, and 
on the release of other mediators by mast cells [3,16,17]. In 
addition, there is evidence that patients who are hypersensitive 
to COX-1 inhibitors tend to produce higher levels of sLTs even 
before exposure to ASA/NSAIDs [3,18]. The role of sLTs 
as major mediators of clinical symptoms in hypersensitivity 
reactions to ASA/NSAIDs is well recognized [2,18,19]. A 
key enzyme, leukotriene C4 synthase, is overexpressed in 
the bronchial mucosa of patients who are hypersensitive to 
NSAIDs [20], with the result that this condition has lately been 
considered a pharmacogenetic disorder [21,22]. The search 
for a single genetic polymorphism associated with NSAID 
hypersensitivity, however, has yielded somewhat contradictory 
results to date [23-27]. 
For the last 20 years, most leading allergologists have 
maintained that there is no in vitro diagnostic test for the NSAID 
hypersensitivity syndrome [3,7,28]. Indeed, traditional cell-based 
allergy tests (eg, the histamine release test), have yielded mostly 
negative results in the case of ASA/NSAID hypersensitivity [29,30]. 
However, the advent of the cellular allergen stimulation test 
(CAST), which is based on release of sLTs by activated blood 
basophils [31-33], presents a challenge to this opinion. Several 
rather anecdotal reports [31-35] and a few well-controlled and 
validated studies [33,36] have clearly shown that ASA/NSAIDs 
can induce basophil activation and sLT release in vitro, at least in a 
sizeable number of  ASA/NSAID–hypersensitive patients. Other 
authors, however, have not confi rmed the phenomenon [37], 
and a superfi cial analysis of the literature reveals a rather 
confusing and contradictory picture. However, as discussed 
elsewhere [38], these apparent contradictions seem to arise 
from technical differences and differences in the interpretation 
of results.
Another recently developed diagnostic technique is based 
on the fl owcytometric evaluation of basophil activation induced 
in vitro by ASA [11,39] and other allergens (fl owcytometric 
allergen stimulation test) [40]. The method has been 
successfully applied to the study of NSAID hypersensitivity 
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syndrome [38,41] and has opened new perspectives for 
understanding its pathophysiology. The diagnostic value 
of the fl owcytometric assay in allergy has recently been 
reviewed [40,42-46].
In this paper, we present the results of the largest series 
of in vitro diagnostic tests reported to date in patients with 
clinically validated NSAID hypersensitivity compared with 
different categories of controls who tolerate NSAIDs. This 
multicenter study, which was performed within the framework 
of the European Network for Drug Allergy (ENDA) group, 
confi rmed that the basophil activation test (BAT, in this study 
the commercially available Flow CAST), particularly when 
used with the 3 NSAIDs ASA, diclofenac (DIC), and naproxen 
(NAP) at 2 concentrations, enables us to confi rm the diagnosis 
of NSAID hypersensitivity syndrome. The results of CAST 
frequently correlate with those of BAT, although not always. 
Our results have been presented elsewhere [44,45,47,52], and 
an unexpected fi nding was that basophil activation by NSAIDs 
is not an all-or-nothing phenomenon restricted to clinically 
hypersensitive patients, but that it also occurs in a dose-related 
manner in some NSAID-tolerant control participants [49]. 
Therefore, NSAID hypersensitivity appears as a shift in the 
normal pharmacological response to NSAIDs. These fi ndings 
make it possible to formulate a new, rational hypothesis 
about the mechanism of NSAID hypersensitivity [44,47,52], 
a mechanism that most authors continue to describe as 
“unknown” [9].
Methods
Patients
A total of 152 patients with a history of hypersensitivity 
to NSAIDs were enrolled in 11 different centers between 
spring 2003 and spring 2006. Complete clinical and 
laboratory data according to the ad hoc ENDA protocol were 
obtained for 144 patients and are evaluated here. There were 
71 (46.7%) men and 81 (53.3%) women aged between 16 and 
71 years (mean 44 years). Most patients were in the third or 
fourth decade of life.
Detailed clinical information was obtained on atopic status 
(39/144, 27.0%), history of allergic reactions to NSAIDs, 
culprit drug(s), presence of symptoms related to other drugs 
at the time of testing, as well as time elapsed since the last 
clinical reaction to NSAIDs. When appropriate, the results 
of re-exposure and provocation tests were also given. The 
history was considered as validated when the clinical reaction 
had been documented by a physician and reproduced with 
classic symptoms after a provocation test within 24 hours 
of administration of ASA at a dose of at least 500 mg. The 
history was considered as likely when the clinical reaction 
had been documented by a physician and when more than 
1 clinical event had been recorded following exposure to 1 
or more NSAIDs 
Among the patients with a provocation-validated or likely 
history of NSAID hypersensitivity, 39 (27%) presented with 
airway symptoms (rhinitis, asthma) only, 97 (67%) presented 
with skin symptoms (urticaria, angioedema) only, and 8 (6%) 
presented with both. 
Similar data were obtained from a total of 136 control 
patients investigated in 8 groups. Seventy-six had no history 
of allergic reactions, 5 had a history of allergic reactions to 
other drugs, and 62 were atopic (45.5%) with a corresponding 
history, and positive skin test and specifi c IgE results to some 
inhalant allergens. They had all tolerated at least 500 mg of 
ASA.
An additional population of 29 healthy blood donors was 
used as controls by one investigation group, although their status 
in terms of clinical tolerance to NSAIDs is not known.
Flowcytometric BAT (Flow CAST)
All the reagents used in this study for BAT and all the 
NSAIDs were provided by the manufacturer (Flow CAST, 
Bühlmann Laboratories, Allschwil, Switzerland). The technique 
followed the manufacturer’s instructions and has been fully 
described elsewhere [41,42,53]. Briefl y, blood was collected 
in EDTA tubes and stored at 4°C; the test was then carried out 
within 24 hours of blood sampling. One milliliter of EDTA 
blood allows up to 2 allergens to be tested. The tubes were 
centrifuged at 200g for 5 minutes at 4°C. The supernatant 
(plasma leukocytes) was pipetted and recentrifuged at 500g for 
10 minutes at 4°C. When the supernatant was decanted, the cell 
pellet was resuspended in 100 µL of stimulation buffer (HEPES 
20 mM, NaCl 133 mM, KCl 5 mM, CaCl2 7 mM, MgCl2 3.5 mM, 
HAS 1 mg/mL,  pH 7.4, containing 10 ng/mL of interleukin [IL] 3) 
per milliliter of blood. In 2 groups (PAM, LIM), the technique 
used for cell isolation was slightly different, that is, whole 
EDTA blood was fi rst centrifuged at 500g for 10 minutes, 
yielding a buffy coat layer that was pipetted, washed, and 
centrifuged, before being reconstituted in the IL 3–containing 
buffer described above.
Subsequently, 50 µL of reconstituted solution of ASA 
(final concentrations, 2 and 0.4 mg/mL), paracetamol 
(fi nal concentrations, 0.025 and 0.005 mg/mL), DIC (fi nal 
concentrations, 0.5 and 0.1 mg/mL), NAP (fi nal concentrations, 
1.2 and 0.25 mg/mL), and metamizole (fi nal concentrations, 
1.2 and 0.25 mg/mL) were added to 50 µL of cell suspension in 
microplate wells. Patients with reactions to other NSAIDs were 
also tested with the culprit drug at several fi nal concentrations, 
of which the maximum value was usually 2 mg/mL. These 
final concentrations were chosen following preliminary 
assays and analysis of dose response-curves (data not 
shown). A monoclonal anti-IgE receptor antibody (Bühlmann 
Laboratories) at 1 µg/mL was used as a positive control.
In order to evaluate baseline values without stimulation,   50 µL 
of stimulation buffer was added to another well and 50 µL of cell 
suspension was added to all wells. The microplate covered with 
an adhesive plastic sheet was then incubated for 40 minutes at 
37°C. One group (LIM) used disposable 5m tubes instead of 
microplates. The reaction was stopped by adding 100 µL of 
HEPES buffer pH 7.3 containing EDTA (HEPES 20 mM, NaCl 
133 mM, KCl 5 mM, EDTA 0.27 mM) as a stopping buffer. 
Plates were then centrifuged at 500g for 5 minutes at 4°C, and 
100 µL of supernatant was pipetted and saved for sLT analysis 
by CAST-enzyme-linked immunosorbent assay (ELISA) in 
a polycarbonate tube, with the LTs binding spontaneously 
to polystyrene (see below). Basophils from the cell pellet 
Clinical Findings and In Vitro Diagnosis in NSAID Hypersensitivity
 J Investig Allergol Clin Immunol 2009; Vol. 19(5): 355-369© 2009 Esmon Publicidad
358
were double labeled by adding 20 µL of staining reagent 
containing prediluted anti-CD63 phycoerythrin (PE)-labeled 
and anti-IgE fl uorescein isothiocyanate (FITC)–labeled 
antibody. After light-protected incubation for 30 minutes 
at 4°C, 3.5 mL of erythrolytic reagent (Ortho-Mune lysing 
reagent, Ortho Diagnostic Systems, San Fernando de 
Henares, Madrid, Spain) were added to each tube and left 
at room temperature for 5 minutes. Cell lysis was stopped 
with 1 mL of washing buffer. After centrifuging for another 
5 minutes at 1000g, the supernatants were decanted and 
500 µL of stopping buffer (or the sheath buffer used for the 
cytometer) was added to each tube, which was then gently 
shaken before fl owcytometric analysis.
Flowcytometric analysis was performed at 488 nm on a 
FACScan fl ow cytometer (Becton Dickinson, Madrid, Spain) 
or similar instrument equipped with 1 or more argon lasers. 
The results were analyzed using CellQuest (Becton Dickinson) 
or an equivalent application. On the histogram of forward 
scatter and side scatter, a fi rst cell gate was defi ned by a bit map 
around the lymphocytes. A second gate was defi ned around 
cells showing high-density fl uorescence with anti-IgE FITC. 
These were identifi ed as basophils. At least 500 basophils 
were counted in each assay. The other parameter analyzed on 
the identifi ed basophils was the CD63 activation marker, as 
described elsewhere [41,42,53].
sLT Assay (CAST-ELISA)
The sLT assay measures the amount of sLT (LTC
4
, LTD
4
, 
LTE
4
) produced by blood leukocytes after in vitro stimulation 
by allergens [32,33]. Following isolation of leukocytes and 
incubation with various NSAIDs as described above, 100 µL 
of supernatant was collected from all wells and frozen at 
–20°C until analysis. Within 1 month, the supernatants were 
analyzed for sLTs using ELISA according to the manufacturer’s 
instructions (CAST-ELISA; Bühlmann Laboratories).
Statistical Analysis
The means of non-normally distributed variables were 
compared using the Mann-Whitney test. Qualitative data 
were compared using the χ2 test with a Yates correction 
when necessary. All P values were 2-tailed, and statistical 
signifi cance was set at a P value of .05. The specifi city and 
sensitivity values were obtained by analysis of different cut 
points on receiver operating characteristic (ROC) curves. 
Sensitivity was calculated using the number of positive cases 
detected by the respective techniques in the study group, and 
specifi city using the number of negative cases detected by the 
same techniques in the control group. The statistical analysis 
was performed using SPSS version 10.0 (SPSS Inc, Chicago, 
Illinois, USA).
Results
As indicated in Table 1, the multicenter study organized 
under ENDA sponsorship included 152 case reports from 
10 groups; 2 groups reported a single case each, and these were 
not included in the fi nal evaluation. Similarly, cases in which 
Table 1. Total Number of Cases Investigated in the NSAID ENDA 
Multicenter Study
a Plasma leukocytes
b Buffy coat leukocytes
Group           Patients  Controls Cell Isolation
AAChen 3 0 a
CRAcow 4 9 a
GRAz 7 12 a
HANover 1 0
LIMoges 9 11 b
LODz 11 10 a
MALaga 8 8 a
NANcy 1 0
PAMplona               78 50 a and b
SETubal 1 7 a
WROclaw 29 29 a and b
BASel 29 a and b
Total 152 165
there was insuffi cient information or incomplete performance 
of the investigation protocol were also excluded, leaving 
140 evaluable cases. The groups provided 136 clinically 
evaluable controls (patients who were tolerant of NSAIDs). 
In addition, 1 group provided 29 healthy blood donors with 
unknown NSAID tolerance.
Several patterns of in vitro reactivity and basophil 
activation detected by BAT (Flow CAST) and CAST were 
observed. Examples of such patterns are given in Table 2. In 
a fi rst evaluation, the positivity cutoff for BAT was established 
at 5% basophil activation and a stimulation index (SI=test 
value/basal value) >2. These values had been established in 
a fi rst study [38,64] by ROC curves. As shown below, they 
retained their operational value in this ENDA multicenter 
study. Considering the results obtained with 5 NSAIDs, but 
particularly the more frequently positive ASA, DIC, and NAP 
with BAT and CAST performed on the same blood samples, 
the main patterns observed were as follows:
a)  Positive results with BAT and CAST to several NSAIDs 
at 1 or 2 concentrations (38 [27%] of the 140 fully 
evaluable patients, 9 [6%] of the 136 evaluable 
controls).
b)  Positive results with BAT only to several NSAIDs at 
1 or 2 concentrations, CAST being mostly negative or 
unknown (42 [30%] of the 140 fully evaluable patients, 
27 [20%] of the 136 evaluable controls). 
c)  Positive results with CAST only to several NSAIDs at 
1 or 2 concentrations, BAT being mostly negative (6 
[4%] of the 140 fully evaluable patients, 6 [4%] of the 
136 evaluable controls).
d) Positive results with BAT (with CAST positive or 
negative) to a single NSAID at 1 or 2 concentrations 
(23 [16%] of the 140 fully evaluable patients, 8 [6%] 
of the 136 evaluable controls). 
e)  Positive results with CAST only (with BAT negative) to 
a single NSAID at 1 or 2 concentrations (5 [4%] of the 
140 fully evaluable patients, 5 [4%] of the 136 evaluable 
controls).
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Table 3. Results of BAT and CAST in Patients With Hypersensitivity to NSAIDs (140 Evaluable Patients)
  
Abbreviations: BAT, basophil activation test; CAST, cellular antigen stimulation test; NSAID, nonsteroidal 
anti-infl ammatory drug.
a To at least one concentration of ASA, DIC, and/or NAP
Sensitivity
BAT-positivea 81 76%
BAT-negative 26
CAST-positive only  7/79 9%
CAST- and BAT-positive 27 /79 34%
B. Not validated  n=33
BAT-positivea 25 76%
BAT-negative 8
CAST-positive only 14%
CAST- and BAT-positive   9 /  22 41%
A. Validated (provocation-positive) n=107 No.
  3 /22
Table 4. Reproducibility of Results in Various Groups of NSAID-Hypersensitive Patients (125 Evaluable Patients)
  
Abbreviations: BAT, basophil activation test; CRA, Cracow; GRA, Graz; LIM, Limoges; LOD, Lodz; MAL, Málaga; NSAID; 
nonsteroidal anti-infl ammatory drug; PAM, Pamplona; SET, Setubal; WRO, Wroclaw.
Group BAT-positive            %
GRA n=7 3 43
CRA n=4 4 100
LIM n=7 3 43
LOD           n=10 9 90
MAL n=8 4 50
PAM n=78 59 75
SET n=1 1 100
WRO n=10 9 90
Table 5. Reproducibility of Controls
  
Abbreviations: BAT, basophil activation test; CRA, Cracow; GRA, Graz; LIM, Limoges; LOD, Lodz; MAL, Málaga; NSAID; 
nonsteroidal anti-infl ammatory drug; PAM, Pamplona; SET, Setubal; WRO, Wroclaw.
a 7 symptomatic instrinsic asthmatics
b Double NSAID concentration
Group BAT Positive %
GRA n=12 4 33
CRA n=9 8a 89
MAL n=8 5 63
LIM n=11 0 0
LOD           n=9 1 12
PAM n=50 5 10
SET n=7 3b 43
WRO n=7 3 43
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f) Totally negative BAT and CAST results to all 5 NSAIDs 
tested (22 [16%] of the 140 fully evaluable patients, 81 
[60%] of the 136 evaluable controls). 
The overall results of BAT and CAST in 140 evaluable 
patients are summarized in Table 3. Patients validated by 
a positive provocation (n=64), mostly to ASA 500 mg or 
more, were fi rst considered separately from those who did 
not undergo provocation testing but had a convincing history 
with at least 2 classic clinical episodes following exposure 
to 1 or more NSAIDs (n=43). In the positive population that 
underwent provocation testing, 40/64 (63%) showed multiple 
positive BAT results (categories A or B). In the population with 
a convincing history (2 or more episodes), 28/43 (65%) showed 
multiple positive BAT results (categories A or B). Entirely 
negative BAT results were obtained in 6 (10%) and 9 (21%) 
patients from the former and latter populations, respectively. 
therefore, both populations were considered validated (Table 3). 
An additional population of 33 cases included patients with 
a single clinical manifestation or a less clear-cut history. One 
or several positive BAT results were observed in about 75% 
of both populations. A positive CAST result was observed in 
about 30% together with a positive BAT result and in about 
10% in the absence of a positive BAT result.
 Since about half of the patients in this multicenter study 
were from a single group (PAM), it was important to assess 
whether this introduced a signifi cant bias and whether the 
percentage of positive patients differed between the groups. 
As can be seen from Table 4, this does not seem to be the 
case, and groups providing 10 patients or more have a similar 
percentage of positive patients.
Very strikingly, however, this does not appear to be the case 
with controls (Table 5). While in 3 groups (PAM, LIM, LOD), 
the number of control cases with positive BAT and/or CAST 
results was very low, resulting in high specifi city, positive 
control cases in most other groups were relatively frequent, 
resulting in poor sensitivity. This was initially unexpected and 
not readily understood, since all groups had allegedly used the 
same protocol and the same reagents. However, further enquiry 
revealed that the 2 groups with low control positivity had used 
a different method for cell isolation and preparation (buffy 
coat) than the technique recommended by the manufacturer 
and used by all the other groups (plasma leukocytes). The 
reasons for this discrepancy are analyzed in more detail below 
and elsewhere [54]. 
Sensitivity and specifi city were calculated for each of the 
5 NSAIDs tested, either by separating the groups using the 
buffy coat or the plasma leukocyte cell isolation technique, 
or by combining them (Table 6). Paracetamol and metamizole 
contributed little to positive results, while ASA, DIC, and 
NAP mostly resulted in parallel positive results. In fact, when 
ASA, DIC, and NAP were considered together, a sensitivity of 
70%-75% was obtained, with specifi city varying from 47% to 
91% depending on the cell isolation method used. It appeared 
that the best results were obtained using both concentrations 
1 and 2, whereas concentration 2 alone was defi nitely less 
sensitive (Table 7).
All the results presented above were obtained using 5% 
basophil activation and an SI >2. This cutoff was based on the 
fi rst series of patients reported [38,41]. A study of the ROC 
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Sensitivity (patients) Specificity (controls)
SE % SP %
Group 1, c1 only b 28/41 68.3 Group 1, c1 only 24/45 46.7
Group 2, c1 only 53/73 79.4 Group 2, c1 only   6/68 91.2
Groups 1+2, c1 only 81/114 71.0 Group 1+2, c1 only 30/113 70.0
Group 1, c2 only 18/41 43.9 Group 1, c2 only   10/45 73.5
Group 2, c2 only 29/73 34.5 Group 2, c2 only  1 /68 98.6
Group 1+1, c2 only 47/114 41.2 Group 1+1, c2 only  11 /113 90.3
Group 1, c1 + c2 31/41 75.6 Group 1, c1 + c2  24 /45 46.7
Group 2, c1 + c2 55/73 75.3 Group 2, c1 + c2   6/68 91.2
Group 1+2, c1+c2 86/114 75.4 Group 1+2, c1+c2  30/ 113 73.5
Table 7. Combined BAT Analysis for ASA, DIC, and NAPa
Abbreviations: ASA, acetylsalicylic acid; BAT, basophil activation test; DIC, diclofenac; NAP, naproxen; SE, sensitivity; SP, specifi city.
a Any or all of the 3 positive 
b BAT-positive/no. tested
curves including the cases of the multicenter study yielded 
essentially the same results (results not shown). The effect of 
choosing a higher cutoff of 8% or 10% for basophil activation 
is shown in Table 8. As expected, increasing the cutoff slightly 
diminishes sensitivity but increases specifi city, thus making it 
less dependent on the cell isolation method used (Table 8). It 
also shows that the plasma leukocyte technique yields higher 
BAT activation values to NSAIDs, increasing sensitivity 
but decreasing specifi city. For some unknown reason, BAT 
activation values to anti-IgE receptor antibody are higher with 
Table 8. BAT Sensitivity in NSAID-Sensitive Patients According to Positivity Criteria (ENDA All Groups)
  
Positivity BAT % Positive ASA DIC NAP ADN Sum
Criterion Baseline Control 1 1
> 5%  50/127 50/116 38/113 41/97 20/93 62/95   >25 SI>2
SE 39 18 43 34 42 22 65
> 8 % 41/127 19/124 46/116 26/113 35/97 16/93 43/95 >50 SI>2
SE 32 15 40 23 36 17 45
 > 10% 31/127 19/124 39/116 25/113 34/97  12/93
SE 24 15 34 22 35 13
Buffy coat leukocyte method
Group Positivity BAT % Positive ASA DIC NAP ADN Sum
Criterion Baseline Control 1 1 0,2
Mean
> 5% 33/84  14/84  26 /73  23 /53  10/53  37/58   >25 SI>2
SE 39 17 36 30 43 19 64
> 8 % 26/84   10/84  23/73  13/73  20/53  6/53 21/58 >50 SI>2
SE 31 12 32 18 38 11 36
 > 19% 19/84  10/84 19/73  12/73  19/53  4/53
SE 23 12 26 16 36 8
Plasma leukocyte method
Group Positivity BAT % Positive ASA DIC NAP DN Positivity Criterion
Criterion Baseline Control 1 1
Mean
> 5%  15/42  9/42  23/42  17/42  17/42  10/42  27/42   >25 SI>2
SE 36 21 54 40 40 24 64
> 8 % 14/42  9/42 22/42  13/42  14/42  10/42 19/42 >50 SI>2
SE 33 21 52 31 33 24 45
 > 19%  11/42  9/42  20/42  13/42  14/42  10/42
SE 26 21 48 31 33 24
Mean 4.16
3.46
5.84
44.89
51.93
33.34
10.63
9.69
12.84
0.2
 22/124
7.91
0.2
6.81
0.2
10.11
0.3
12.24
0.3
9.7
0.3
17.36
0.06
8.94
0.06
22/73
6.6
0.06
12.96
12.49
11.88
13.72 8.95
0.2
5.72
0.2
7.213 50.61
40.18
74.59
ADN Positivity CriterionGroup
Pos/no.
Pos/no.
Pos/no.
Pos/no.
Pos/no.
Pos/no.
Pos/no.
Pos/no.
Pos/no.
ADN Positivity Criterion
ADN Sum A
Abbreviations: ADN, acetylsalicylic acid-diclofenac-naproxen; ASA, acetylsalicylic acid; BAT, basophil activation test; ENDA, European Network for Drug 
Allergy; NAP, naproxen; pos, positive. 
buffy coat leukocytes than with plasma leukocytes (Table 9).
If we examine the results for individual patients, it quickly 
becomes clear that most NSAID-hypersensitive patients, 
when BAT positive, react to ASA, DIC, and NAP (Figure 1), 
often with a quantitative correlation of the activation values 
obtained (ASA/DIC, r=0.67; ASA/NAP, r=0.77; DIC/NAP, 
r=0.69). In order to facilitate clinical evaluation of the results, 
we combined the values obtained in a so-called ADN index 
(ASA/DIC/NAP). This index is calculated by adding the BAT 
values (as a percentage) for 2 concentrations of ASA, DIC, 
J Investig Allergol Clin Immunol 2009; Vol. 19(5): 355-369 © 2009 Esmon Publicidad
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Table 9. BAT Specifi city in Controls According to Positivity Criteria in Control
  
Abbreviations: ADN, acetylsalicylic acid-diclofenac-naproxen; ASA, acetylsalicylic acid; BAT, basophil activation test; DIC, diclofenac; NAP, naproxen; pos, 
positive; SP, specifi city. 
Controls all groups
Positivity BAT % Positive DIC NAP ADN Sum ADN Positivity Criterion
Criterion Baseline Control 1 1
Mean 3 criterion
  > 5%  14/111 6/111 20/97   10/97  15/89  4/89   17/85
SP 87 95 79 89 83 95 80  >25  SI>2
 > 8 %   9/111  2/111  17/97  7/97  10/89  2/89  9/87
SP 92 98 82 92 88 97 90  >50 SI>2
> 10%  5/111  1/111  15/97  6/97  6/89  1/89
SP 95 99 84 94 93 99
Buffy coat leukocyte method
Positivity BAT % Positive DIC NAP ADN Sum ADN Positivity Criterion
Criterion Baseline Control 1 0,2 0,3 1
Mean 42,26 criterion
 > 5%  2 /61   0/61   3 /50   1/50     4/41   1/41   2 /50
SP 97 100 94 98 90 98 96  >25  SI>2
 > 8%  0/61  0/61   2/50   1/50   0/41  1/41  1/50
SP 100 100 96 98 100 98 98  >50 SI>2
 > 10%  0/61  0/61  1/50   1/50   0/41   1/41
SP 100 100 98 98 100 98
Plasma leukocyte method
Positivity BAT % Positive ASA DIC NAP ADN Sum ADN Positivity Criterion
Criterion Baseline Control 1 0,2 1
Mean criterion
 >5%  12/50   6/49  16/46   8/43  11/46  3/43   15 /43
SP 76 88 65 81 76 93 65  >25  SI>2
 > 8%  8/50  2/49   14/46  5/43   10/46   1/43   8/43
SP 84 96 70 88 78 98 81  >50 SI>2
 > 10%  5/50  1/49   11/46   4/43  6/46   0/43
SP 90 98 76 91 87 100
ASA
3.81
ASA
2.5
5.42
0.2
2.6
2.05
3.28
0.3
6.34
3.71
0.3
8.64
0.06
3.78
0.06
2.83
0.06
4.87 6.08
2.08
4.26 3.03
0.2
0.2
2.55
0.2
3.38 27.1
19.25
12.4
37.08
2.61
3.44 31.21
Pos/no.
Pos/no.
Pos/no.
Pos/no.
Pos/no.
Pos/no.
Pos/no.
Pos/no.
Pos/no.
Table 10. Combined ASA, DIC, and NAP Using the ADN Index
Abbreviations: ADN, acetylsalicylic acid-diclofenac-naproxen; ASA, acetylsalicylic acid; DIC, diclofenac; 
ENDA, European Network for Drug Allergy; NAP, naproxen; SI, stimulation index.
ADN Index Sensitivity, % Speci?city, %
ENDA all cases  SI>25 65 80
SI>50 45 3
ENDA Buffy coat  SI>25 64 96
SI>50 36 98
ENDA Leukocytes  SI>25 64 65
SI>50 45 81
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and NAP and subtracting 6 times the negative control baseline 
value from the sum obtained. As shown in Table 10, such a 
calculation does not markedly affect sensitivity when the 
ADN index is >25, since evaluation with a positive criterion 
of 5% basophil activation to any of the 3 NSAIDs has already 
identifi ed a maximum of BAT-positive patients. However, the 
ADN index increases specifi city by magnifying the difference 
between clinically positive patients and negative controls 
with an occasional positive BAT result. This is also clear 
from Figure 2. The ADN index also enables a quantitative 
evaluation to be made. In Tables 8 and 9, the highest sensitivity 
manifested by the plasma leukocyte cell isolation technique is 
also manifested by a higher ADN index.
As for CAST, there is clearly a correlation between the 
results of BAT and CAST in a sizeable number of patients. 
With a cutoff point for CAST of 100 pg/mL greater than the 
baseline value and an SI >2, 46 patients of 101 tested (45.5%) 
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Figure 1. Correlation of basophil activation test results between acetylsalicylic acid, diclofenac, and naproxen among patients with NSAID hypersensitivity 
syndrome. NSAID indicates nonsteroidal anti-infl ammatory drug; C, concentration.
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acetylsalicylic acid-diclofenac-naproxen.
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Figure 5. Dose-response curves for acetylsalicylic acid, diclofenac, and naproxen in hypersensitive patients and controls. The number of test points are 
given for both patients and controls.
were CAST-positive (Table 3); 36 of 101 (35.6%) were positive 
to both BAT and CAST. The correlation is not only qualitative 
(pos/neg) but also quantitative (Figures 3 and 4). It is, however, 
markedly higher for basophil activation induced by anti-IgE 
receptor antibody than for stimulation induced by ASA (Figure 3) 
or NAP (Figure 4). A number of patients have a positive BAT 
result but negative CAST results to several NSAIDs and vice 
versa.
It is also obvious that the BAT activation response to 
NSAIDs is dose-dependent, both in clinically hypersensitive 
patients and in controls. This is already apparent with 
the 2 concentrations used in the ENDA multicenter study 
(concentrations 1 and 2 in Tables 6, 8, and 9), although it 
became even more evident when 2 additional concentrations, 
one higher than concentration 1 and one lower than 
concentration 2 were used in a number of patients and controls 
(Figure 5) (detailed results not shown). The difference between 
controls and patients in their BAT response to NSAIDs in vitro 
is represented by a shift in their dose-response curve.
Several authors highlight the problem of so-called BAT 
nonresponders, which makes it impossible to interpret 
the results in as many as 8%-10% of cases [43,53]. In 
this multicenter study, 14 patients of the 152 tested (10%) 
were nonresponders to the BAT-positive control (anti-IgE 
receptor antibody). However, they were all positive to 
CAST performed on the same sample, thus qualifying them 
as false nonresponders, an artifact that has been elucidated 
elsewhere [53] and no longer occurs in later phases of the 
study. Accordingly, true nonresponders amounted in this study 
to 0/152 (0%) in patients and 1/152 (0.6%) in controls. 
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Discussion
The characteristics of our study population correspond 
to the classic descriptions of NSAID hypersensitivity 
syndrome [3,7-10]. For most patients, the syndrome started in 
the third to fourth decade of life and manifested in the airways 
or on skin. It was often preceded by episodes of rhinitis and 
asthma or urticaria before the ability of NSAIDs to elicit 
symptoms became evident. The preponderance of patients 
with skin symptoms in this collective is probably due to the 
fact that most groups participating in the study were from 
allergy or dermatology departments, and very few were from 
internal medicine or pneumology departments. When analyzed 
separately, however, patients with cutaneous or respiratory 
symptoms had the same percentage (64%-65%) of strongly 
positive BAT results, thus enabling them to be considered 
together. Other authors have shown a similar mechanism 
between these 2 categories of patients [55].
Most of the study patients (107/140 evaluated) can be 
considered as validated, that is, they had experienced NSAID 
hypersensitivity syndrome, since they had positive results to 
provocation testing with ASA or presented a history of at least 
2 clinical events with 1 or more NSAIDs. As shown, both 
groups yielded a similar percentage of multiple positive BAT 
results (63%-65%). Even in the 33 patients with a less clear-
cut clinical validation, it appears that the clinical history was 
reliable, since the percentage of strongly positive BAT results 
was quite similar, although with a slightly higher percentage 
of negative test results.
NSAID hypersensitivity syndrome does not appear to be 
related to atopy, since most patients (about 75%) have neither 
a history of nor positive test results (IgE, skin tests) for atopy. 
In controls, the proportion of atopic patients was markedly 
higher (about 45%), probably refl ecting the population of 
patients easily available in an allergy department. However, 
all of the controls were shown by provocation to be clinically 
tolerant to ASA.
As can be seen from Table 2 and the results presented 
above, 57% of 140 patients presented very clear-cut positive 
BAT results (categories A and B) to multiple NSAIDs and 
16% were entirely negative, making interpretation easy. In 
about 27% of cases, positive results were obtained with 1 or 
2 concentrations of a single NSAID.
In patients with a validated history, the BAT results were 
relatively homogeneous between the groups, particularly 
when a larger number of patients (7 or more) were studied 
(Table 3). However, extensive heterogeneity was observed 
in controls (Table 4). This could be due to the clinical status 
of patients taken as controls. For example, in most groups, a 
sizeable number of controls were asymptomatic individuals 
with no signs or history of allergic reactions. In 1 group (CRA), 
however, all controls had perennially active asthma and were 
under treatment at the time of the BAT, although they showed 
negative results to a provocation test with ASA. In this group, 
7 out of 9 presented multiple positive BAT results. However, in 
another group (LOD) of 10 controls also affl icted by perennial 
asthma and rhinitis but negative ASA asthma provocation, 
none presented a positive BAT result. Therefore, the question 
remains open as to whether patients with respiratory symptoms 
(asthma, rhinitis) or cutaneous symptoms (urticaria) are more 
prone to basophil activation in vitro by NSAIDs, even if they 
tolerate them clinically. Other studies [56] have demonstrated 
that patients who are symptomatic at the time of basophil-based 
tests are more prone to basophil activation.
Another major factor in the heterogeneity of controls seems 
to be the cell isolation technique used. This study revealed, 
apparently for the fi rst time, that a number of control patients, 
even those who tolerated ASA, clearly show dose-dependent 
basophil activation in vitro by NSAIDs. Furthermore, this 
activation appears more pronounced and more frequent when 
plasma leukocytes rather than buffy coat cells are used for the 
BAT (Tables 6, 8, and 9). This phenomenon is further analyzed 
and discussed elsewhere [54].
Our results clearly show that NSAID hypersensitivity 
in vitro is not an all-or-nothing qualitative phenomenon, 
but rather a shift in the dose-response curve that appears to 
occur in parallel for various NSAIDs. Indeed, reactivity to 
ASA, DIC, and NAP appears to be quantitatively correlated 
(Figure 1). It is also obvious that the BAT tests are much easier 
to interpret when performed with several NSAIDs (ASA, DIC, 
and NAP), at least at 2 concentrations. This makes it possible 
to interpret results using the corresponding combined ADN index 
(Figure 2). Some previous negative or less favorable reports in 
the literature on the results of basophil-based in vitro tests in 
NSAID-hypersensitive patients [30] included only 1 NSAID, 
sometimes at only 1 markedly lower concentration [37], and 
are therefore easily explainable. Furthermore, reviewers should 
no longer consider that such reports contradict other positive 
fi ndings obtained under different technical conditions. It is 
always important to consider the details.
The finding that clinical hypersensitivity to NSAIDs 
is often accompanied by dose-dependent in vitro basophil 
hypersensitivity is not revolutionary. It corresponds rather 
well with the hypothesis that NSAID hypersensitivity is 
not an immunological but a pharmacological phenomenon 
related to the inhibitory effect of these drugs on prostaglandin 
synthesis [4]. The fact that some controls that are clinically 
tolerant to NSAIDs show positive BAT results and that some 
clinically hypersensitive patients show negative BAT results 
does not invalidate the hypothesis. It is well documented that 
the minimum NSAID dose needed to elicit clinical symptoms 
can vary by a factor of as much as 100 (eg, 5-500 mg) in 
hypersensitive patients. Conditions of in vitro and in vivo 
administration are also very different. It would be interesting, 
although cumbersome, to evaluate by progressive provocation 
in vivo whether the dose-response curve in vivo parallels the 
BAT dose-response curve in vitro.  
Although BAT with NSAIDs does not correlate completely 
with clinical provocation in qualitative terms–about a quarter 
of provocation-positive patients have negative results in 
BAT–there is no doubt that patients with a clinical history 
of allergy to NSAIDs supported by positive provocation test 
results have signifi cantly more positive BAT results than 
individuals with no history who tolerate NSAIDs. The BAT 
with several NSAIDs at 2 appropriate concentrations appears 
to have confi rmatory diagnostic value when positive. It should 
no longer be legitimate to state that no in vitro tests exist 
for that condition [3]. In addition, these fi ndings add new 
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elements to the discussion on the pathogenesis of NSAID 
hypersensitivity syndrome, as discussed in greater detail 
elsewhere [44,47,52].
There also appears to be an association between the 
results of CAST (based on production of sLTs by NSAIDs 
from basophils in vitro) and clinical NSAID hypersensitivity 
syndrome, as shown elsewhere [33,34,36] and as confi rmed 
by this multicenter study. Some negative reports [37] appear 
to be due to suboptimal or inappropriate technical conditions, 
as discussed elsewhere [53]. Nevertheless, in practice, there 
is no absolute parallelism between BAT and CAST results 
(as we show here), since CAST shows positive results in 
only about half of the BAT-positive cases. CAST is positive 
alone in only about 6% of the cases with a clinical history and 
positive NSAID provocation results. The reasons for such 
discrepancies are manifold. BAT and CAST detect different 
steps in basophil activation, and these steps may be infl uenced 
by various factors on an individual basis. For example, we have 
clearly established that BAT is more dependent than CAST on 
the external Ca+ concentration [53]. In practical terms, it seems 
that the BAT has greater diagnostic value than CAST under 
the conditions used in that study.
BAT seems particularly indicated in patients with a clinical 
history of NSAID intolerance in whom a provocation test is 
not advisable for ethical, clinical, or other reasons. Clear-cut 
positive results can be considered as confi rming a history 
of NSAID hypersensitivity, while negative results may not 
exclude it. This situation is similar to that of many in vitro 
tests in drug hypersensitivity (eg, lymphocyte transformation 
test).
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